Literature DB >> 3987784

Atenolol inhibits the elimination of disopyramide.

J Bonde, S Bødtker, H R Angelo, T L Svendsen, J P Kampmann.   

Abstract

The effect of atenolol on the total elimination of disopyramide and its main dealkylated metabolite was studied in 6 patients and 3 volunteers. During administration of 50 mg atenolol b.i.d. the clearance of disopyramide decreased significantly (p less than 0.02) from 1.90 +/- 0.71 (mean +/- SD) to 1.59 +/- 0.68 ml/kg/min, while its half-life, concentration of the metabolite, and the volume of distribution remained unchanged. The reduction in the clearance of disopyramide by atenolol might contribute to the alleged pharmacodynamic interaction between disopyramide and beta-blocking drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987784     DOI: 10.1007/bf00635706

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite.

Authors:  J J Lima
Journal:  Clin Chem       Date:  1979-03       Impact factor: 8.327

2.  A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function.

Authors:  B N Singh
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

3.  Interaction between disopyramide and practolol.

Authors:  A D Cumming; C Robertson
Journal:  Br Med J       Date:  1979-11-17

Review 4.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

5.  The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.

Authors:  W F Cathcart-Rake; J E Coker; F L Atkins; D H Huffman; K M Hassanein; D D Shen; D L Azarnoff
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

6.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

7.  Disopyramide kinetics in renal impairment: determinants of interindividual variability.

Authors:  M Burk; U Peters
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

8.  Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism.

Authors:  H Perrild; J M Hansen; L Skovsted; L K Christensen
Journal:  Clin Endocrinol (Oxf)       Date:  1983-02       Impact factor: 3.478

9.  The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.

Authors:  D A Deano; D Wu; R K Mautner; R H Sherman; A I Ehsani; K M Rosen
Journal:  Chest       Date:  1977-05       Impact factor: 9.410

  9 in total
  5 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 3.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 4.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease.

Authors:  J Bonde; L E Pedersen; H R Angelo; J Trap-Jensen; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.